Raymond James Financial Services Advisors Inc. Trims Position in Ascendis Pharma A/S (NASDAQ:ASND)

Raymond James Financial Services Advisors Inc. decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 45.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,224 shares of the biotechnology company’s stock after selling 6,766 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Ascendis Pharma A/S were worth $1,036,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Wellington Management Group LLP grew its holdings in shares of Ascendis Pharma A/S by 14.6% during the first quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock worth $547,552,000 after purchasing an additional 594,855 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Ascendis Pharma A/S by 4.7% in the third quarter. Westfield Capital Management Co. LP now owns 3,802,177 shares of the biotechnology company’s stock worth $356,036,000 after buying an additional 170,465 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Ascendis Pharma A/S by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,828,267 shares of the biotechnology company’s stock worth $345,417,000 after buying an additional 796,087 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Ascendis Pharma A/S by 3,024.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock worth $205,903,000 after buying an additional 1,698,302 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Ascendis Pharma A/S by 16.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company’s stock worth $118,405,000 after buying an additional 176,948 shares in the last quarter.

Wall Street Analyst Weigh In

ASND has been the subject of several research reports. Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research note on Wednesday, December 20th. They issued a “buy” rating and a $150.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, April 1st. Citigroup boosted their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Finally, Wedbush boosted their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average price target of $173.25.

Ascendis Pharma A/S Stock Down 3.3 %

Shares of Ascendis Pharma A/S stock opened at $146.04 on Monday. The company has a market cap of $8.50 billion, a PE ratio of -15.79 and a beta of 0.50. The business has a 50 day moving average of $149.06 and a 200 day moving average of $122.93. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.18 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.